Healthcare / BiotechnologyNasdaqCM
$4.19
+0.04 (+0.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
0.0x
↓EV/EBITDA
-6.0x
↓ROE
15.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-3.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $1.0M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $1.0M | $1.0M | $-51.2M | $-3.2M | $-1.9M |
| EBITDA | $1.0M | $1.0M | $-51.1M | $-3.2M | $-1.9M |
| EPS | 261.02 | 261.02 | -14274.29 | -940.02 | -544.78 |
| Balance Sheet | |||||
| Debt/Equity | — | — | -0.95 | — | — |
| Current Ratio | 8.09 | 8.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-3.0M | $-1.6M | $-1.4M |
| Returns | |||||
| ROE | 15.1% | 15.1% | 466.2% | 1599.6% | -109.3% |
| Valuation | |||||
| P/E | 0.02 | 0.02 | — | — | — |
| EV/EBITDA | -5.97 | -5.97 | — | — | — |
| P/B | 0.00 | 0.00 | — | — | 470.67 |
| Growth & Yield | |||||
| EPS Growth | 101.8% | 101.8% | -1418.5% | -72.6% | — |
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-88.7%
EPS terminal req.
$0.37
Spread vs growth
190.6%
5Y implied EPS CAGR
-72.0%
EPS terminal req.
$0.45
Spread vs growth
173.8%
10Y implied EPS CAGR
-44.5%
EPS terminal req.
$0.72
Spread vs growth
146.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-97.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-14274.29 → 261.02
Residual
-97.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.